Deep Genomics Funding, Investors & Competitors

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Heyuan Biotechnology is a Chinese provider of gene therapy services, specializing in AAV and lentiviral vector production, CRISPR-based gene editing, and in vivo efficacy testing. Operating from facilities certified under ISO 13485, it supports pharma clients with plasmid design, viral packaging at titers exceeding 10^13 vg/mL, and animal model studies for CNS and oncology targets.

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Merck KGaA operates in three main segments: life science, electronics, and healthcare. The life science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck family publicly sold part of the company, resulting in the current 30% public ownership of the firm.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

IonQ Inc sells access to several quantum computers of various qubit capacities and is in the process of researching and developing technologies for quantum computers with increasing computational capabilities. The company currently makes access to its quantum computers available via cloud platforms and also to select customers via its own cloud service. This cloud-based approach enables the broad availability of quantum-computing-as-a-service (QCaaS). The company derives its revenue from its quantum-computing-as-a-service arrangements, consulting services related to co-developing algorithms on company's quantum computing systems and contracts associated with the design, development, and construction of specialized quantum computing systems together with related services.

Applied Intuition is a Mountain View-headquartered developer of simulation software, Vehicle OS, and self-driving toolchains for AI-driven autonomous vehicles. The company accelerates deployment across automotive, defense, trucking, construction, mining, and agriculture sectors. Major global automakers and Department of Defense programs rely on its platforms to validate sensor suites, perception stacks, and planning algorithms. Founded in 2017, Applied Intuition maintains offices in Washington, D.C., San Diego, Ann Arbor, London, Stuttgart, Munich, Stockholm, Bangalore, Seoul, and Tokyo to support international engineering teams.

Skild AI is a San Francisco-headquartered startup building foundation models for robotics that enable spatial intelligence and adaptive manipulation in unstructured environments. The company trains multimodal AI on real-world data from humanoid robots to handle tasks like grasping and navigation without task-specific programming. Skild AI raised funding from investors including Benchmark and focuses on warehouse automation and manufacturing applications.

SambaNova is a Palo Alto-headquartered enterprise AI company providing full-stack solutions from Reconfigurable Dataflow Unit silicon like the 2023 SN40L chip to software platforms including Samba Cloud for instant inference on models such as Llama and Qwen, SambaStack for on-premise deployments, and SambaManaged for efficient data center AI services deployable in 90 days.

Institut Mérieux is a biomedical research foundation based in Lyon, France, developing diagnostics, vaccines, and therapies against infectious diseases and cancer. Part of the Mérieux family enterprises, it funds projects in antibiotic resistance, emerging pathogens, and immuno-oncology through partnerships with INSERM and international consortia like CEPI.

Automation Anywhere is a leader in robotic process automation with its cloud-native platform combining RPA, AI, process discovery, and analytics. Founded in 2003 and San Jose-headquartered, it automates tasks across finance, HR, and IT for enterprises worldwide. The IQ Bot handles document processing, while Bot Store offers pre-built automations. Automation Anywhere serves sectors in over 180 countries with integrations to SAP and ServiceNow.

Intrepid Labs is a biotechnology firm spun out of the University of Toronto in 2022. The company applies artificial intelligence and robotics to automate drug formulation processes, speeding up therapeutic development for pharmaceuticals. Its platform optimizes solid oral dosage forms by predicting formulation outcomes and reducing trial-and-error iterations. Based in Toronto, Ontario, Intrepid Labs partners with contract development organizations to enhance efficiency in early-stage drug manufacturing pipelines.

Positron is a provider of specialized hardware accelerators for transformer model inference in generative AI applications. Its chips deliver high-throughput processing with reduced power usage compared to GPU alternatives. The platform supports every model in the Hugging Face Transformers library and exposes an OpenAI-compatible API endpoint. Developers deploy custom-trained models directly onto Positron hardware for edge and cloud deployments in natural language processing and computer vision tasks.

Color is a health technology platform delivering population genomics, cancer screening, and COVID-19 testing programs for employers, schools, and governments. Headquartered in Burlingame, California, it processes whole-genome sequencing through CLIA-certified labs and partners with health systems like Kaiser Permanente for nationwide deployment.

Ricursive Intelligence is a frontier AI lab founded in December 2025 by former Google DeepMind researchers Dr. Anna Goldie and Dr. Azalia Mirhoseini that automates and accelerates semiconductor design through a self-improving recursive loop. By building platforms that use artificial intelligence to design next-generation silicon chips—which in turn provide the advanced compute needed to train more powerful AI models—the company aims to shift the semiconductor industry toward a "designless" paradigm that bypasses traditional hardware bottlenecks on the path to artificial superintelligence.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.